Study on medical treatment for patients with reflux esophagitis refractory to proton pump inhibitor
- Conditions
- Reflux esophagitis
- Registration Number
- JPRN-UMIN000003911
- Lead Sponsor
- Department of Gastroenterology, Kobe University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
(1) Patients with the past history of digestive tract excisio and vagotomy (2) Patients who have alert symptoms such as nausea, gastrointestinal bleeding and rapid weight loss (3) Patients who have past history of or suffer from the following diseases: Zollinger-Ellison symdrome, inflammatory bowel disease, esophageal stenosis, achalasia, malabsorption, cerebrovascular disease such as cerebral hemorrhage or cerebral infarction (4) Patients having severe liver, kidney or heart disease (5) Patients who have malignancy or are suspected of having malignancy (6) Patients who are pregnant, in breast-feeding or may have cecome pregnant (7) Patients who need continuous medication of atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus, digoxin, methyldigoxin, itraconazole, Gefinitinib or voriconazole that might interact with the test drug (8) Patients who are receiving proton pump inhibitors except rabeprazole (9) Patients whom the doctor in charge judged to be unsuitable as an object of this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in scores of Frequency scale for symptoms of gastroesophageal reflux diseases (FSSG)
- Secondary Outcome Measures
Name Time Method 1)Changes in scores of gastrointestinal symptom rating scale (GSRS) 2)Subgroup analysis for CYP2C19 genotype